Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
OCUL Ocular Therapeutix, Inc. daily Stock Chart
OCUL [NASD]
Ocular Therapeutix, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.57 Insider Own0.50% Shs Outstand42.97M Perf Week-3.17%
Market Cap157.27M Forward P/E- EPS next Y-0.82 Insider Trans146.93% Shs Float37.56M Perf Month-12.02%
Income-60.00M PEG- EPS next Q-0.42 Inst Own51.80% Short Float19.60% Perf Quarter-7.11%
Sales2.00M P/S78.64 EPS this Y28.50% Inst Trans0.84% Short Ratio14.49 Perf Half Y-42.54%
Book/sh0.87 P/B4.21 EPS next Y46.10% ROA-82.60% Target Price13.83 Perf Year-43.52%
Cash/sh- P/C- EPS next 5Y- ROE-136.10% 52W Range3.46 - 8.28 Perf YTD-8.04%
Dividend- P/FCF- EPS past 5Y-19.40% ROI-97.40% 52W High-55.78% Beta1.79
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin76.60% 52W Low5.78% ATR0.20
Employees167 Current Ratio6.10 Sales Q/Q0.00% Oper. Margin- RSI (14)40.09 Volatility5.21% 5.19%
OptionableYes Debt/Eq0.69 EPS Q/Q4.80% Profit Margin- Rel Volume0.84 Prev Close3.64
ShortableYes LT Debt/Eq0.69 EarningsMar 07 AMC Payout- Avg Volume508.03K Price3.66
Recom1.80 SMA20-8.41% SMA50-10.01% SMA200-29.43% Volume424,348 Change0.55%
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-13-15Initiated Morgan Stanley Overweight $24
Aug-05-15Initiated Nomura Buy $46
Apr-08-15Reiterated RBC Capital Mkts Outperform $50 → $48
Mar-11-15Reiterated RBC Capital Mkts Outperform $35 → $50
Mar-11-15Reiterated Oppenheimer Outperform $42 → $49
Jan-30-15Reiterated Oppenheimer Outperform $25 → $42
Apr-03-19 08:00AM  Ocular Therapeutix to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Apr-02-19 08:15AM  Ocular Therapeutix Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Mar-26-19 11:51AM  Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks
Mar-25-19 08:00AM  Ocular Therapeutix Reports Election of Leslie Williams to Board of Directors Business Wire
Mar-21-19 09:00AM  Ocular Therapeutix to Host 2019 Research & Development Day Business Wire
Mar-14-19 09:34AM  Edited Transcript of OCUL earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-19 08:35PM  Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Ocular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update Business Wire
Mar-05-19 08:00AM  Ocular Therapeutix to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire
Mar-01-19 08:00AM  Ocular Therapeutix To Report Fourth Quarter and Year End 2018 Financial Results Business Wire
Feb-22-19 02:40PM  Watch These Four Biotech Stocks Friday ACCESSWIRE +15.24%
Feb-21-19 09:25PM  Ocular Therapeutix Prices $37.5 Million Subordinated Convertible Debt Financing Business Wire
Feb-20-19 08:30AM  Ocular Therapeutix Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD) Business Wire
Feb-06-19 12:30PM  Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company? Simply Wall St.
Jan-22-19 07:40AM  Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-19 10:32AM  Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza Zacks
08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga
Jan-10-19 04:01PM  Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Jan-07-19 09:00AM  Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Business Wire
Dec-28-18 08:00AM  Ocular Therapeutix Announces Completion of Debt Refinancing Business Wire +6.72%
Dec-26-18 10:56AM  Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-20-18 11:00AM  Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock? Simply Wall St.
08:00AM  Ocular Therapeutix Added to Nasdaq Biotechnology Index Business Wire
Dec-06-18 08:00AM  Ocular Therapeutix Announces the Hiring of Chad Brines, Vice President, Sales Business Wire +8.20%
Dec-04-18 08:59AM  Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock Zacks
Dec-03-18 08:23AM  CORRECTING and REPLACING Ocular Therapeutix Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery Business Wire -13.96%
Nov-21-18 08:00AM  Ocular Therapeutix to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 06:35PM  H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks SmarterAnalyst +5.95%
Nov-12-18 07:40AM  Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 06:35PM  Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:36PM  Ocular Therapeutix: 3Q Earnings Snapshot Associated Press
04:01PM  Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update Business Wire
Oct-31-18 08:00AM  Ocular Therapeutix To Report Third Quarter 2018 Financial Results Business Wire
Oct-30-18 10:33AM  Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know Zacks -5.08%
Oct-22-18 02:54PM  Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst SmarterAnalyst
Oct-19-18 08:09AM  Ocular Therapeutix stock drops 10% after FDA warning letter MarketWatch
07:50AM  Ocular Therapeutix Receives FDA Warning Letter Related to ReSure® Sealant Business Wire
Oct-18-18 08:55AM  Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire
Oct-11-18 12:57PM  Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St.
Oct-10-18 04:26PM  Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst -5.62%
Sep-26-18 08:00AM  Ocular Therapeutix to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-11-18 10:11AM  Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 12:36PM  Here's Why Ocular Therapeutix Jumped 21.6% in August Motley Fool
Aug-29-18 08:00AM  Ocular Therapeutix to Present at the H.C. Wainwright 20th Annual Global Investment Conference Business Wire
Aug-27-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix New Research Emphasizes Economic Growth GlobeNewswire
Aug-21-18 07:15PM  Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares GuruFocus.com
Aug-20-18 01:00PM  JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL) SmarterAnalyst
Aug-07-18 05:20PM  Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:17PM  Ocular Therapeutix: 2Q Earnings Snapshot Associated Press
04:00PM  Ocular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update Business Wire
Jul-31-18 04:00PM  Ocular Therapeutix To Report Second Quarter 2018 Financial Results Business Wire
Jul-19-18 08:00AM  Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA® Business Wire
05:53AM  Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-18-18 07:26AM  Ocular Therapeutix (OCUL) Enters Oversold Territory Zacks
Jun-29-18 08:00AM  Ocular Therapeutix Announces NDA Resubmission of DEXTENZA Business Wire -6.90%
Jun-22-18 07:55AM  Report: Developing Opportunities within Mercantile Bank, Kindred Healthcare, Ocular Therapeutix, Roper Technologies, Milacron, and First Defiance Financial Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-12-18 08:00AM  Ocular Therapeutix to Present at the 2018 JMP Securities Life Sciences Conference Business Wire +6.34%
May-29-18 10:24AM  5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace
May-14-18 09:52PM  Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:10PM  Ocular Therapeutix: 1Q Earnings Snapshot Associated Press
04:01PM  Ocular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Business Wire
May-03-18 08:38AM  Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension Business Wire
07:45AM  Investor Expectations to Drive Momentum within Quaker Chemical, Ocular Therapeutix, Viad, Ingredion, LivePerson, and Tableau Software Discovering Underlying Factors of Influence GlobeNewswire
Apr-27-18 08:00AM  Ocular Therapeutix to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire
Apr-26-18 04:01PM  Ocular Therapeutix to Report First Quarter 2018 Financial Results Business Wire
Apr-09-18 04:30PM  Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium Business Wire
10:29AM  Biotechs Take the Lead This Morning TheStreet.com
Apr-03-18 03:11PM  Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St.
Mar-22-18 04:36PM  Ocular Therapeutix To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 Business Wire
06:40AM  Can the Rally in Ocular Therapeutix (OCUL) Shares Continue? Zacks
Mar-16-18 01:11AM  Edited Transcript of OCUL earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents +9.94%
Mar-15-18 08:30PM  Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic? Simply Wall St.
Mar-09-18 08:20AM  Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-08-18 01:00PM  Under SEC scrutiny, Bedfords Ocular Therapeutix plans FDA do-over American City Business Journals
09:23AM  Ocular Therapeutix reports 4Q loss Associated Press
07:30AM  Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update Business Wire
06:35AM  Want To Invest In Ocular Therapeutix Inc (NASDAQ:OCUL)? Heres How It Performed Lately Simply Wall St.
Feb-28-18 08:00AM  Ocular Therapeutix to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire
Feb-27-18 04:00PM  Ocular Therapeutix To Report Fourth Quarter 2017 Financial Results Business Wire
Feb-21-18 08:02AM  Top 3 Stocks Insiders Are Buying Simply Wall St. +5.85%
Feb-08-18 08:00AM  Ocular Therapeutix to Participate in the 2018 Glaucoma 360 Meeting in San Francisco Business Wire
Jan-29-18 04:01PM  Ocular TherapeutixTM Announces Closing of Public Offering of Common Stock Business Wire +6.91%
Jan-25-18 09:11AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga -14.22%
09:09AM  Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock Business Wire
Jan-24-18 04:01PM  Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire
Jan-08-18 08:20AM  New Research Coverage Highlights TTM Technologies, LogMeIn, Ocular Therapeutix, Everbridge, Power Integrations, and CBIZ Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
08:00AM  Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality Business Wire
Jan-01-18 09:15AM  Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-26-17 11:55AM  ETFs with exposure to Ocular Therapeutix, Inc. : December 26, 2017 Capital Cube
Dec-22-17 04:56PM  Ocular Therapeutix gets subpoena from SEC over eye pain drug Reuters
04:05PM  Ocular Therapeutix Provides Legal Update Business Wire
Dec-13-17 04:54PM  Is It Too Late To Buy Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. +9.84%
Dec-05-17 08:00AM  Ocular Therapeutix to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference Business Wire
Dec-04-17 12:00PM  Was Ocular Therapeutix Incs (OCUL) EPS Decline A Part Of Broader Industry Downturn? Simply Wall St.
Nov-20-17 08:03PM  Robbins Arroyo LLP Investigates the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire -5.84%
Nov-13-17 04:05PM  Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:25PM  Ocular Therapeutix reports 3Q loss Associated Press -6.06%
04:05PM  Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:50PM  Ocular Therapeutix Inc to Host Earnings Call ACCESSWIRE
Oct-31-17 08:00AM  Ocular Therapeutix to Report Third Quarter 2017 Financial Results Business Wire
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heier Jeffrey S.DirectorMar 15Buy4.1524,00099,60024,000Mar 18 06:20 PM
Goldstein Michael H.Chief Medical OfficerMar 15Buy4.1510,00041,50013,686Mar 18 06:20 PM
LINDSTROM RICHARD L MDDirectorMar 13Buy4.3356,441244,390100,000Mar 14 04:14 PM
Hanley Kevin F.See RemarksDec 14Buy5.5010,00055,00020,000Dec 18 08:52 AM
Hanley Kevin F.SEE REMARKSDec 10Buy5.6010,00056,00010,000Dec 12 04:35 PM
Bollag Daniel MSee RemarksDec 06Buy5.7617,400100,22442,100Dec 10 04:15 PM
Mattessich Antony C.President & CEOAug 20Buy5.9520,000119,00057,900Aug 21 04:30 PM
Notman DonaldChief Financial OfficerAug 14Buy6.2912,50078,62517,300Aug 15 05:13 PM
Mattessich Antony C.President and CEOAug 10Buy6.2316,900105,28737,900Aug 13 04:43 PM
open in yahoo | open in reuters | open in google